Schedule III is here — and the hemp clock is ticking.

The DOJ–DEA Schedule III final rule landed Friday with a 60-day comment window. Independent of that, the 2024 Farm Bill extension's hemp redefinition takes effect November 12 — total-THC accounting (Δ9-THC + THCA × 0.877) replaces Δ9-only at the federal level. Three states moved on THCA this week. Comment-period close: July 17.

Why it matters: Operators shipping any non-Δ9 cannabinoid product to states with delta-8 bans now have a federal data point their counsel can cite — the agency's clarification removes one layer of ambiguity that's been sitting unresolved since the 2024 Farm Bill draft.

DEA's Office of Diversion Control issued a clarification on May 14 indicating that synthetically-derived delta-8 THC remains a Schedule I controlled substance under existing regulations, regardless of source material. Naturally-occurring delta-8 in hemp-derived products at trace levels (<0.3% Δ9 by dry weight) is not affected. The clarification is non-binding but signals the agency's enforcement posture going into the November 12 total-THC transition.

Why it matters: First movement on the FDA's hemp-CBD docket since 2023. Ingredient manufacturers and contract formulators should refresh comment-period submissions; the 90-day window closes August 11.

FDA's Center for Food Safety and Applied Nutrition reopened comment docket FDA-2023-N-0094 on May 13, citing "new pharmacokinetic data" submitted by three industry petitioners. The reopened docket specifically addresses cannabidiol as a food additive, not as a dietary supplement — the supplement pathway remains closed.

Why it matters: Operators with NY distribution need to pull non-compliant SKUs from shelves within 30 days or face $5,000 per-violation penalties. The rule's "synthetic" definition is broader than the federal one.

The NY Department of Health published emergency regulation 10 NYCRR Part 1005 on May 17, treating any cannabinoid produced via isomerization as a Schedule I controlled substance regardless of source. The rule gives a 30-day compliance window for existing inventory. A public hearing is scheduled for June 24.

Why it matters: The bill would require all intoxicating-hemp products to be sold only through licensed cannabis dispensaries — closing the CBD/hemp-shop retail channel for delta-8, delta-9 gummies, and THCA flower statewide. Operators with retail-channel revenue should prepare contingency plans.

SB 1457 passed the Senate Business, Professions and Economic Development Committee 8-2 on May 15 with bipartisan support. The bill creates a new "industrial hemp consumable" license category and makes possession by non-cannabis-licensed retailers a misdemeanor. Sponsor Sen. Mike McGuire (D-Healdsburg) projects a Senate floor vote before the July 12 recess.

Why it matters: Texas hemp-flower operators face a real enforcement risk for the first time. Lab COAs that report Δ9 only without total-THC are now audit-exposed. Refresh COA templates and reserve sample retention.

Texas Department of State Health Services began a 90-day random-audit program for licensed hemp manufacturers on May 12. The program tests total-THC (including THCA conversion) and revokes manufacturer licenses for products exceeding 0.3% total-THC on a dry-weight basis. Two manufacturer licenses were revoked the first week.

Why it matters: The methodology divergence between states is closing fast. Multi-state operators can plan against one standard (total-THC via Δ9 + THCA × 0.877) for compliance, but should preserve state-specific reporting columns for state-level licensing.

Colorado, Oregon, and Michigan all updated lab-testing requirements this week to require total-THC reporting alongside individual cannabinoid values. The 0.877 conversion factor (the molecular-weight ratio between Δ9-THC and THCA after decarboxylation) matches the federal rule taking effect November 12. Oregon's update includes retroactive COA revisions for products in distribution.

Why it matters: The amendment expands the existing Cannabis Act (CanG) to include regulated commercial sales pilots in four metropolitan areas. US operators with EU subsidiaries should track the pilot-license timeline.

The Bundestag advanced amendment 20/24158 on May 13, authorizing commercial cannabis sales pilots in Berlin, Hamburg, Frankfurt, and Munich for adults 21+. The pilot is limited to 18 months and 200 retail locations total. License applications open July 1.

Why it matters: UK-distributing CBD operators have a 60-day window to submit pharmacokinetic data without re-validating an existing dossier. Coordinate with your regulatory affairs lead before the July 15 close.

The Medicines and Healthcare products Regulatory Agency reopened the novel-foods consultation on May 16, accepting new pharmacokinetic evidence on cannabidiol absorption and metabolism. The consultation runs through July 15. CBD products currently authorized under the previous 2020 regime are unaffected.

Why it matters: Hemp-CBD shippers can plan around continued USPS access, but the revised PS Form 1717 documentation requirement adds ~3 minutes per shipment. Shippers should refresh their fulfillment SOPs by October 15.

USPS Office of Mailability published Publication 52 revision on May 14 confirming that hemp and hemp-derived products meeting the new total-THC standard remain mailable through First-Class Mail and Priority Mail. The revision adds a mandatory PS Form 1717-A certification for shipments exceeding 1 kilogram.

Two ways to get answers — instant AI for interpretation questions, or a real attorney for matters that need counsel.

New here? The explainers most-read by operators and counsel this quarter:

Three referrals unlock the 50-state legality PDF. Ten unlock 30 minutes with the editor. Twenty-five gets you a sponsor slot at half price.

One sponsor per issue. From $500. Specific audience: cannabis & hemp compliance officers, regulatory attorneys, MSO executives.